Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression

American Journal of Pathology

Volumn 168, Issue 1, 2006, Pages 270-279

  Simian, Marina ^a,b   Molinolo, Alfrede ^a,c   Lanari, Claudia ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b Instituto de Oncologia Angel H Roffo   (Argentina)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; ESTRADIOL; GELATINASE A; GELATINASE B; HORMONE; LAMININ; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEDROSTERONA; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; PROGESTERONE; STROMELYSIN; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST TUMOR; CELL INTERACTION; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; HORMONAL THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; STROMA; TUMOR CELL LINE; TUMOR REGRESSION;

EID: 30344466614     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.050012     Document Type: Article

References (34)

1. Parkin DM: International variation. Oncogene 2004, 23:6329-6340
2. Lacey Jr JV, Devesa SS, Brinton LA: Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 2002, 39:82-88
3. Werb Z: ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997, 91:439-442
4. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516
5. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174
6. Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 2001, 411:375-379
7. Coussens LM, Tinkle CL, Hanahan D, Werb Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490
8. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392
9. Lanari C, Molinolo AA, Pasqualini CD: Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett 1986, 33:215-223
10. Molinolo AA, Lanari C, Charreau EH, Sanjuan N, Pasqualini CD: Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors. J Natl Cancer Inst 1987, 79:1341-1350
11. Kordon E, Lanari C, Molinolo AA, Elizalde PV, Charreau EH, Dosne PC: Estrogen inhibition of MPA-induced mouse mammary tumor transplants. Int J Cancer 1991, 49:900-905
12. Montecchia MF, Molinolo A, Lanari C: Reversal of estrogen-resistance in murine mammary adenocarcinomas. Breast Cancer Res Treat 1999, 54:93-99
13. Talhouk RS, Bissell MJ, Werb Z: Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol 1992, 118:1271-1282
14. Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z: Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 1996, 122:181-193
15. Boudreau N, Sympson CJ, Werb Z, Bissell MJ: Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995, 267:891-893
16. Institute of Laboratory Animal Resources CoLSNRC: Guide for the Care and Use of Laboratory Animals. Washington, DC, National Academy Press, 1996
17. Lanari C, Luthy I, Lamb CA, Fabris V, Pagano E, Helguero LA, Sanjuan N, Merani S, Molinolo AA: Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins. Cancer Res 2001, 61:293-302
18. Lanari C, Montecchia MF, Pazos P, Simian M, Vanzulli S, Lamb C, Molinolo AA: Progestin-induced mammary adenocarcinomas in BALB/c mice. Progression from hormone-dependent to autonomous tumors. Medicina (B-Aires) 1997, 57(Suppl 2):55-69
19. Vanzulli S, Efeyan A, Benavides F, Helguero LA, Peters G, Shen J, Conti CJ, Lanari C, Molinolo A: p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis 2002, 23:749-758
20. Horwitz KB, Tung L, Takimoto GS: Novel mechanisms of antiprogestin action. Acta Oncol 1996, 35:129-140
21. Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257
22. Talhouk RS, Chin JR, Unemori EN, Werb Z, Bissell MJ: Proteinases of the mammary gland: developmental regulation in vivo and vectorial secretion in culture. Development 1991, 112:439-449
23. Simian M, Hirai Y, Navre M, Werb Z, Lochter A, Bissell MJ: The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development 2001, 128:3117-3131
24. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997, 139:1861-1872
25. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ: Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003, 39:462-468
26. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW: Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J Cell Sci 2002, 115:39-50
27. Scheithauer M, Riechelmann H: Basic mechanisms of cutaneous woundhealing. Laryngorhinootologie 2003, 82:31-35
28. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, Bissell MJ, Ronnov-Jessen L: Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 2003, 162:391-402
29. Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA, Day ML: Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer Res 2001, 61:489-492
30. Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, Rubin MA, Day ML: The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res 2003, 9:6447-6452
31. Rios-Doria J, Day KC, Kuefer R, Rashid MG, Chinnaiyan AM, Rubin MA, Day ML: The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 2003, 278:1372-1379
32. Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, Day KC: E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem 1999, 274:9656-9664
33. Cheon SS, Nadesan P, Poon R, Alman BA: Growth factors regulate beta-catenin-mediated TCP-dependent transcriptional activation in fibroblasts during the proliferate phase of wound healing. Exp Cell Res 2004, 293:267-274
34. Labus MB, Stirk CM, Thompson WD, Melvin WT: Expression of Wnt genes in early wound healing. Wound Repair Regen 1998, 6:58-64